Metabolite identification of bentysrepinine (Y101), a novel anti-HBV agent in rats using a five-step strategy based on a combined workflow with two different platforms of liquid chromatography-tandem mass spectrometry.

•This is the first metabolic investigation of Y101.•A five-step strategy based on LC-QTRAP-MS/MS and LC-QTOF-MS/MS was successfully applied to identify metabolites of Y101.•It is important for a better understanding of metabolic fate of Y101 in rats and may act as a reference for clinical pharmacology.